Posted On: 09/15/2014 2:28:21 PM
Post# of 30066
I was just asking you which catalysts you think will make my old target of .40 cents look conservative by December? It's a fair question. You've told me that probably 6 or 7 times!
In small Bio-tech stocks I have learned not to treat them like my wife. My wife I will stay with forever, but I never make that kind of commitment to a stock. I too think AMBS looks great long term, 1.5 to 4 years from now. But I also pay attention to what the stock is doing here and now in terms of how well management executes and keeps their promises. How well a company executes in the short term does say something about it's long term outlook.
It is never wise to stick your head in the sand regarding a stock's current performance, simply because you believe it's long term outlook is great. String enough short term quarterly disappointments together, and it's not long before the long term outlook changes. (Pushing back up listing from Q2 2014 to Q1 2015) You always have to keep an eye on management's execution. I was not impressed with Gerald's execution of presenting LymPro to the world in July. Nevertheless, in spite of that, I am staying long, but I am definitely more cautious than I was even three weeks ago when the master service agreement was announced. We can make it with ICON, but the margin by which we succeed just got a lot narrower!
In small Bio-tech stocks I have learned not to treat them like my wife. My wife I will stay with forever, but I never make that kind of commitment to a stock. I too think AMBS looks great long term, 1.5 to 4 years from now. But I also pay attention to what the stock is doing here and now in terms of how well management executes and keeps their promises. How well a company executes in the short term does say something about it's long term outlook.
It is never wise to stick your head in the sand regarding a stock's current performance, simply because you believe it's long term outlook is great. String enough short term quarterly disappointments together, and it's not long before the long term outlook changes. (Pushing back up listing from Q2 2014 to Q1 2015) You always have to keep an eye on management's execution. I was not impressed with Gerald's execution of presenting LymPro to the world in July. Nevertheless, in spite of that, I am staying long, but I am definitely more cautious than I was even three weeks ago when the master service agreement was announced. We can make it with ICON, but the margin by which we succeed just got a lot narrower!
(0)
(0)
